Lead Product(s) : Ropocamptide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds
Details : The most important finding from that clinical trial was that ropocamptide (LL-37) shows a significant effect in the patient subgroup with large wounds (≥10 cm2).
Product Name : LL-37
Product Type : Peptide
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Ropocamptide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropocamptide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DecentraNet
Deal Size : $10.8 million
Deal Type : Financing
Maxwell Biosciences Raises $10.8 Million in Oversubscribed Seed Round
Details : The funding will enable Maxwell to accelerate the development of its innovative platform having LL-37, recruit and retain top talent, pursue clinical trials, and scale up manufacturing capabilities.
Product Name : LL-37
Product Type : Peptide
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : Ropocamptide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DecentraNet
Deal Size : $10.8 million
Deal Type : Financing